AMYLYX PHARMACEUTICALS INC

Amylyx has shifted its business model toward rare niche diseases after the Relyvrio setback. The drug Avexitide delivered convincing phase-3 data, opening access for the company to a previously unserved multibillion-dollar market for postbariatric hypoglycemia. A successful capital raise secures financing well into 2028 and enables the planned commercial launch. As a result, the stock posts a strong gain. » Mere på finanzen.net

In the phase-3 study LUCIDITY, Avexitide reduced postbariatric hypoglycemia events of levels 2 and 3 by 55% versus placebo and met the primary and secondary endpoints agreed with the FDA. This substantially increases the chances of a submission for approval. The news triggered a rally; the stock rose about 65% to a 3.5-year high and continued higher on follow-on buying. » Mere på finanzen.net

Avexitide reduced hypoglycemia by 55% in the Phase-3 LUCIDITY study, which is being regarded as a decisive breakthrough. Amylyx Pharmaceuticals’ stock rose about 89.6% in one month. The company, which focuses on rare diseases, is thus moving closer to a potential FDA approval for Avexitide. » Mere på finanzen.net